Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients

L. Licitra, R. Cavina, C. Grandi, S. Di Palma, M. Guzzo, R. Demicheli, R. Molinari

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.

Original languageEnglish
Pages (from-to)640-642
Number of pages3
JournalAnnals of Oncology
Volume7
Issue number6
Publication statusPublished - Aug 1996

Fingerprint

Salivary Glands
Doxorubicin
Cyclophosphamide
Cisplatin
Carcinoma
Histology
Radiotherapy
Drug Therapy
Survival
Pharmaceutical Preparations

Keywords

  • Advanced salivary gland carcinoma
  • CAP regimen
  • Chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. / Licitra, L.; Cavina, R.; Grandi, C.; Di Palma, S.; Guzzo, M.; Demicheli, R.; Molinari, R.

In: Annals of Oncology, Vol. 7, No. 6, 08.1996, p. 640-642.

Research output: Contribution to journalArticle

@article{90a03a36153648fdbd6279e7564478b1,
title = "Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients",
abstract = "Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27{\%}, 95{\%} CI: 11{\%}-50{\%}): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27{\%}. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.",
keywords = "Advanced salivary gland carcinoma, CAP regimen, Chemotherapy",
author = "L. Licitra and R. Cavina and C. Grandi and {Di Palma}, S. and M. Guzzo and R. Demicheli and R. Molinari",
year = "1996",
month = "8",
language = "English",
volume = "7",
pages = "640--642",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients

AU - Licitra, L.

AU - Cavina, R.

AU - Grandi, C.

AU - Di Palma, S.

AU - Guzzo, M.

AU - Demicheli, R.

AU - Molinari, R.

PY - 1996/8

Y1 - 1996/8

N2 - Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.

AB - Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.

KW - Advanced salivary gland carcinoma

KW - CAP regimen

KW - Chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029792962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029792962&partnerID=8YFLogxK

M3 - Article

C2 - 8879381

AN - SCOPUS:0029792962

VL - 7

SP - 640

EP - 642

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -